09 Jul 2012, BioSpectrum Bureau , BioSpectrum
Singapore: The International Court of Arbitration, International Chamber of Commerce, has issued its arbitral award in the arbitration filed by R-Tech Ueno, together with Sucampo Pharmaceuticals and Sucampo AG, against Takeda Pharmaceutical. The arbitral award stipulated that the claims of R-Tech Ueno were not accepted and the supply agreement among R-Tech Ueno, Takeda and Sucampo executed in 2004 regarding the exclusive supply of AMITIZA capsules shall continue to be in effect. No damages were rendered.
R-Tech Ueno will continue to supply Amitiza capsules to Takeda based on the supply agreement. Although R-Tech Ueno has not announced its business forecast for the fiscal year ending March 2013, it will do after consideration of the arbitration result.